Xeljanz
FDA Warns of Serious Risks, Including Death, With Tofacitinib
The FDA is requiring the addition of warnings about increased risks for cancer, serious cardiovascular events and ...
SEPTEMBER 2, 2021
FDA Warns of Possible Serious CV Events, Cancer Linked to Xeljanz
The FDA issued an alert concerning an increased risk for serious cardiovascular events and malignancies with the ...
FEBRUARY 5, 2021
FDA Issues New Boxed Warning for Xeljanz, Xeljanz XR
Twice-daily 10-mg dose of tofacitinib increased risk of blood clots and death.
JULY 26, 2019
Higher Dose of Xeljanz Increased Clot Risk in RA Study
The FDA alerted health professionals and the public about an increased risk for pulmonary embolism and death when a ...
FEBRUARY 27, 2019
Load more